| Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer (NCT07714447) | Sun Yat-sen University | 2026-11-30 |
| Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) (NCT07255612) | Sun Yat-sen University | 2026-11-04 |
| Full-wrap Versus Conventional Suspension for Reducing Soft Palate Injury Rate in Transoral Surgery (NCT07552545) | Sun Yat-sen University | 2026-09-30 |
| Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma (NCT07766889) | Sun Yat-sen University | 2026-09-01 |
| Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma (NCT07550855) | Sun Yat-sen University | 2026-09-01 |
| Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study (NCT07756190) | Sun Yat-sen University | 2026-09-01 |
| Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma (NCT07701681) | Sun Yat-sen University | 2026-08-31 |
| Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases (NCT07745257) | Sun Yat-sen University | 2026-08-28 |
| Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile Cancer (NCT07767266) | Sun Yat-sen University | 2026-08-15 |
| Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma (NCT07753642) | Sun Yat-sen University | 2026-08-15 |
| Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL (NCT07409168) | Sun Yat-sen University | 2026-08-15 |
| Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma (NCT07064902) | Sun Yat-sen University | 2026-08-01 |
| Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC (NCT07674524) | Sun Yat-sen University | 2026-08-01 |
| Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy (NCT07594912) | Sun Yat-sen University | 2026-08-01 |
| Culmerciclib in HR+/HER2+ Advanced Breast Cancer (NCT07732491) | Sun Yat-sen University | 2026-08-01 |
| Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer (NCT07751055) | Sun Yat-sen University | 2026-08-01 |
| Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma (NCT07645846) | Sun Yat-sen University | 2026-07-31 |
| QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer (NCT07636226) | Sun Yat-sen University | 2026-07-30 |
| Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma (NCT07661771) | Sun Yat-sen University | 2026-07-24 |
| Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma (NCT07528183) | Sun Yat-sen University | 2026-07-22 |
| Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma (NCT07705243) | Sun Yat-sen University | 2026-07-20 |
| Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma (NCT07706985) | Sun Yat-sen University | 2026-07-20 |
| Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer (NCT07646301) | Sun Yat-sen University | 2026-07-01 |
| Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome (NCT07729592) | Sun Yat-sen University | 2026-07-01 |
| Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities (NCT07630077) | Sun Yat-sen University | 2026-07-01 |
| Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma (NCT07654465) | Sun Yat-sen University | 2026-07-01 |
| Study on the Effects and Mechanisms of Probiotic Supplementation in Ameliorating Uric Acid Metabolism in Asymptomatic Hyperuricemic Individuals (NCT07650214) | Sun Yat-sen University | 2026-07-01 |
| New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes (NCT07635953) | Sun Yat-sen University | 2026-07-01 |
| Nudging for Anticoagulation Adherence in Atrial Fibrillation (NCT07543393) | Sun Yat-sen University | 2026-06-30 |
| Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (NCT07638436) | Sun Yat-sen University | 2026-06-17 |
| Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma (NCT07542912) | Sun Yat-sen University | 2026-06-01 |
| Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC (NCT07603661) | Sun Yat-sen University | 2026-06-01 |
| FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) (NCT07621497) | Sun Yat-sen University | 2026-06-01 |
| Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma (NCT07622784) | Sun Yat-sen University | 2026-06-01 |
| Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC (NCT07609121) | Sun Yat-sen University | 2026-06-01 |
| Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD) (NCT07581782) | Sun Yat-sen University | 2026-06-01 |
| Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer (NCT07610720) | Sun Yat-sen University | 2026-06-01 |
| Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT07601607) | Sun Yat-sen University | 2026-05-30 |
| Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors (NCT07584499) | Sun Yat-sen University | 2026-05-30 |
| Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma (NCT07615283) | Sun Yat-sen University | 2026-05-29 |
| AI-Assisted Optimization of Online Adaptive Radiotherapy for Gastric Lymphoma (NCT07609355) | Sun Yat-sen University | 2026-05-08 |
| GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. (NCT07540390) | Sun Yat-sen University | 2026-05-08 |
| A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma (NCT07574528) | Sun Yat-sen University | 2026-05-06 |
| Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma (NCT07567742) | Sun Yat-sen University | 2026-05-06 |
| Intrathecal Morphine for Quality of Recovery After Open Abdominal Surgery Within an Enhanced Recovery Pathway (NCT07575321) | Sun Yat-sen University | 2026-05-01 |
| Goniotomy in Primary Congenital Glaucoma (NCT07550868) | Sun Yat-sen University | 2026-05-01 |
| Phosphate-Containing Replacement Fluid for Patients Undergoing CRRT (NCT07550894) | Sun Yat-sen University | 2026-05-01 |
| Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study (NCT07589049) | Sun Yat-sen University | 2026-05-01 |
| SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC (NCT07489703) | Sun Yat-sen University | 2026-04-30 |
| A Descriptive Study of the Correlation Between Postpartum Depression and Body Image Dissatisfaction, Self-objectification, and Social Media Appearance Comparison (NCT07603063) | Sun Yat-sen University | 2026-04-28 |
| BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression (NCT07618624) | Sun Yat-sen University | 2026-04-20 |
| Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer (NCT07528209) | Sun Yat-sen University | 2026-04-20 |
| Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study (NCT07549906) | Sun Yat-sen University | 2026-04-20 |
| Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma (NCT07555860) | Sun Yat-sen University | 2026-04-20 |
| Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles (NCT07522281) | Sun Yat-sen University | 2026-04-15 |
| Effects and Mechanisms of Dietary Carbohydrate Intake and Quality on Glucose and Lipid Metabolism (NCT07533513) | Sun Yat-sen University | 2026-04-13 |
| QL1706 Plus Lenvatinib in Previously Treated Penile Cancer (NCT07384416) | Sun Yat-sen University | 2026-04-10 |
| A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer (NCT07507526) | Sun Yat-sen University | 2026-04-01 |
| Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy (NCT07497958) | Sun Yat-sen University | 2026-04-01 |
| Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL (NCT07415980) | Sun Yat-sen University | 2026-04-01 |
| A Short-Bout Combined Aerobic and Resistance Exercise Program in Older Adults With Diabetes and Probable Sarcopenia (NCT07522359) | Sun Yat-sen University | 2026-04-01 |
| Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma (NCT07524413) | Sun Yat-sen University | 2026-04-01 |
| A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates (NCT07520760) | Sun Yat-sen University | 2026-04-01 |
| Effects of Different Tunnel Methods in PICC Catheterization (NCT07594704) | Sun Yat-sen University | 2026-04-01 |
| Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer (NCT06768931) | Sun Yat-sen University | 2026-04-01 |
| Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. (NCT07320963) | Sun Yat-sen University | 2026-03-31 |
| Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer (NCT07469956) | Sun Yat-sen University | 2026-03-31 |
| Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma (NCT07518602) | Sun Yat-sen University | 2026-03-27 |
| Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer (NCT07530445) | Sun Yat-sen University | 2026-03-23 |
| Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (NCT07477626) | Sun Yat-sen University | 2026-03-20 |
| Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases (NCT07481786) | Sun Yat-sen University | 2026-03-20 |
| TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk (NCT07487662) | Sun Yat-sen University | 2026-03-18 |
| Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer (NCT07448142) | Sun Yat-sen University | 2026-03-15 |
| Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT07463677) | Sun Yat-sen University | 2026-03-15 |
| Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma (NCT07362979) | Sun Yat-sen University | 2026-03-12 |
| Construction and Evaluation of a Flipped Discharge Model for Stomates With Colorectal Cancer (NCT07463690) | Sun Yat-sen University | 2026-03-10 |
| Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL (NCT07494565) | Sun Yat-sen University | 2026-03-06 |
| FMD and Neoadjuvant Chemo-immunotherapy in TNBC (NCT07378306) | Sun Yat-sen University | 2026-03-05 |
| Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma (NCT07385079) | Sun Yat-sen University | 2026-03-01 |
| ArcFlex Sheath in TAVR Trial (NCT07320274) | Sun Yat-sen University | 2026-03-01 |
| Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study (NCT07398638) | Sun Yat-sen University | 2026-02-28 |
| Theory-Based Parenting Intervention for Preschool Children's Health Behaviors (NCT07458009) | Sun Yat-sen University | 2026-02-28 |
| Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial (NCT07413146) | Sun Yat-sen University | 2026-02-24 |
| Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma (NCT07402538) | Sun Yat-sen University | 2026-02-24 |
| Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer (NCT07405736) | Sun Yat-sen University | 2026-02-24 |
| Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (NCT07496190) | Sun Yat-sen University | 2026-02-10 |
| A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma (NCT07392320) | Sun Yat-sen University | 2026-02-10 |
| PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC (NCT07332247) | Sun Yat-sen University | 2026-02-03 |
| SBRT Versus Surgical Resection for Small HCC (NCT07381660) | Sun Yat-sen University | 2026-02-01 |
| Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT07388758) | Sun Yat-sen University | 2026-02-01 |
| The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia (NCT07515430) | Sun Yat-sen University | 2026-02-01 |
| FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma (NCT07353827) | Sun Yat-sen University | 2026-02-01 |
| TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (NCT07342738) | Sun Yat-sen University | 2026-02-01 |
| A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients. (NCT07334093) | Sun Yat-sen University | 2026-01-31 |
| Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial (NCT07380633) | Sun Yat-sen University | 2026-01-23 |
| Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma (NCT07373990) | Sun Yat-sen University | 2026-01-15 |
| Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma (NCT07324824) | Sun Yat-sen University | 2026-01-14 |
| LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC (NCT07325539) | Sun Yat-sen University | 2026-01-12 |
| Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line (NCT07501351) | Sun Yat-sen University | 2026-01-05 |
| A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer (NCT07235618) | Sun Yat-sen University | 2026-01-05 |